Cargando…
“Back to a false normality”: new intriguing mechanisms of resistance to PARP inhibitors
Several evidences have shown that BRCA mutations increased tumor-cells sensitivity to PARP inhibitors by synthetic lethality leading to an accelerated development of several compounds targeting the PARP enzymes system as anticancer agents for clinical setting. Most of such compounds have been invest...
Autores principales: | Incorvaia, Lorena, Passiglia, Francesc, Rizzo, Sergio, Galvano, Antonio, Listȶ, Angela, Barraco, Nadia, Maragliano, Rossella, Calò, Valentina, Natoli, Clara, Ciaccio, Marcello, Bazan, Viviana, Russo, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410353/ https://www.ncbi.nlm.nih.gov/pubmed/28055979 http://dx.doi.org/10.18632/oncotarget.14409 |
Ejemplares similares
-
Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1
por: Badalamenti, Giuseppe, et al.
Publicado: (2019) -
Monitoring blood biomarkers to predict nivolumab effectiveness in
NSCLC patients
por: Passiglia, Francesco, et al.
Publicado: (2019) -
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis
por: Galvano, Antonio, et al.
Publicado: (2019) -
Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups
por: Passiglia, Francesco, et al.
Publicado: (2021) -
How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis
por: Galvano, Antonio, et al.
Publicado: (2019)